Recruiting TP53 to target chronic myeloid leukemia stem cells.
作者信息
Grant Steven
机构信息
Virginia Commonwealth University, Richmond, VA, USA.
出版信息
Haematologica. 2020 May;105(5):1172-1174. doi: 10.3324/haematol.2019.246306.
Abstract
摘要
相似文献
1
Recruiting TP53 to target chronic myeloid leukemia stem cells.
Haematologica. 2020 May;105(5):1172-1174. doi: 10.3324/haematol.2019.246306.
2
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
Leukemia. 2012 Mar;26(3):465-74. doi: 10.1038/leu.2011.239. Epub 2011 Sep 9.
3
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Blood. 2005 Jan 1;105(1):324-34. doi: 10.1182/blood-2003-12-4369. Epub 2004 Aug 26.
4
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.
5
6
Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Tumour Biol. 2017 Jun;39(6):1010428317713394. doi: 10.1177/1010428317713394.
7
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Methods Mol Biol. 2016;1465:187-205. doi: 10.1007/978-1-4939-4011-0_16.
8
C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Leukemia. 2013 Mar;27(3):619-28. doi: 10.1038/leu.2012.258. Epub 2012 Sep 5.
9
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Cancer Biol Ther. 2019;20(6):877-885. doi: 10.1080/15384047.2019.1579958. Epub 2019 Mar 20.
10
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
Oncogene. 2002 Dec 9;21(56):8629-42. doi: 10.1038/sj.onc.1206090.
引用本文的文献
1
Tyrosine Kinase Inhibitor Therapy Enhances Stem Cells Profile and May Contribute to Survival of Chronic Myeloid Leukemiastem Cells.
J Clin Med. 2025 Jan 10;14(2):392. doi: 10.3390/jcm14020392.
2
Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Stem Cell Res Ther. 2021 Dec 18;12(1):603. doi: 10.1186/s13287-021-02659-1.
3
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Int J Mol Sci. 2021 Jan 11;22(2):659. doi: 10.3390/ijms22020659.
本文引用的文献
1
CD34 acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax.
Haematologica. 2020 Aug;105(8):e399-e403. doi: 10.3324/haematol.2019.229997. Epub 2019 Nov 14.
2
A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML.
Oncol Lett. 2019 Nov;18(5):5481-5489. doi: 10.3892/ol.2019.10891. Epub 2019 Sep 19.
3
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
Haematologica. 2020 May;105(5):1274-1284. doi: 10.3324/haematol.2019.219261. Epub 2019 Aug 1.
4
Current status and new treatment approaches in TP53 mutated AML.
Best Pract Res Clin Haematol. 2019 Jun;32(2):134-144. doi: 10.1016/j.beha.2019.05.004. Epub 2019 May 11.
5
Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Future Oncol. 2019 Jan;15(3):257-269. doi: 10.2217/fon-2018-0371. Epub 2018 Sep 25.
6
Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Int J Hematol. 2018 Oct;108(4):365-370. doi: 10.1007/s12185-018-2519-y. Epub 2018 Aug 28.
7
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Sci Transl Med. 2016 Sep 7;8(355):355ra117. doi: 10.1126/scitranslmed.aag1180.
8
Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Neoplasma. 2016;63(4):495-503. doi: 10.4149/neo_2016_401.
9
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Oncotarget. 2015 Oct 13;6(31):30487-99. doi: 10.18632/oncotarget.5890.
10
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
Leukemia. 2011 Jun;25(6):985-94. doi: 10.1038/leu.2011.55. Epub 2011 Apr 5.
Zotero 插件